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Abstract Nephrolithiasis is a known side effect of
indinavir sulfate, a protease inhibitor used in the
treatment of human immunodeﬁciency virus (HIV).
The duration of its side effects, however, has not been
well deﬁned. We present a case where a patient
presented with symptomatic indinavir-induced neph-
rolithiasis 3.5 years after discontinuing indinavir. We
use this case to illustrate the pathophysiology of
indinavir stones and hypothesize how they can occur
years after discontinuation by discussing the phar-
macokinetics of the drug.
Background
Indinavir sulfate is a protease inhibitor used in the
treatment of HIV by inhibiting the cleavage of
precursor polyproteins into functional infectious
proteins. Indinavir-induced nephrolithiasis is a well-
reported side effect of the medication, with an
incidence of approximately 12.4% necessitating dis-
continuation of the drug and altering the antiretroviral
regimen in a considerable number of individuals [1].
However, little is known regarding the occurrence of
indinavir-induced nephrolithiasis after cessation of
indinavir therapy. Case reports have suggested that
indinavir nephrolithiasis can occur up to 11 months
after discontinuation of the drug [2]. We describe a
patient who presents with gross hematuria where
eventual workup revealed indinavir-induced nephro-
lithiasis 3.5 years after the cessation of indinavir.
Case history
A 49-year-old man with HIV presented with gross
hematuria and powdery penile discharge with urina-
tion for the past 1 year. The patient also complained
of mild lower back/ﬂank pain but denied a history of
dysuria, fevers, or chills. He attributed these symp-
toms to fatigue and long-distance air ﬂights.
The patient was diagnosed with HIV in 1989 and
treated with a highly active anti-retroviral therapy
(HAART) regimen that included indinavir at a dose
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DOI 10.1007/s11255-010-9751-6of 800 mg PO TID for 8 years. The indinavir was
discontinued in February 2005 when he developed
nephrolithiasis presumably due to indinavir stones
(no stones were retained for analysis). At the time, he
presented with gross hematuria and ﬂank pain. He
underwent a computed tomography imaging of
kidney ureter bladder (CT KUB) which demonstrated
mild bilateral hydronephrosis and right hydroureter
consistent with obstruction although no radioopaque
calculi were seen. Indinavir was subsequently dis-
continued and the patient’s symptoms resolved with
conservative management. A follow-up renal furose-
mide washout scan showed no evidence of stone or
obstruction suggesting that the patient had passed the
stones resulting in resolution of symptoms.
In September 2006, the patient underwent a kidney
biopsy for a persistently elevated creatinine of
1.6 mg/dl. The biopsy revealed crystal-induced tubu-
lar injury with rupture, acute tubular necrosis, and
arterial and arteriolar nephrosclerosis (Fig. 1). On
electron microscopy, granulamatous giant cell reac-
tion with indinavir crystals within the lumen was seen
(Fig. 2).
The patient again presented with gross hematuria
and right ﬂank pain in September 2008. A urine
analysis revealed pH 6.5, 3? hemoglobin, 1? protein,
positive leukocyte esterase, and a negative urine
culture. Serum creatinine was 2.3 mg/dl. A CT KUB
showed complete resolution of the previously
mentioned left hydronephrosis but moderate dilatation
of the right intrarenal collecting system and right
ureter and again no evidence of calculi. The patient
eventually passed multiple stones with resolution of
symptoms and improvement of serum creatinine to
1.8 mg/dl.Stoneanalysisperformedthistimerevealed
indinavir as the primary composition. The patient had
last taken indinavir 3.5 years ago.
Discussion
Indinavir is primarily metabolized by the liver with
20% eliminated through urine, approximately half of
which is unchanged [1]. Indinavir crystallization
occurs at a urine concentration of 100 mg/l which
corresponds to a plasma concentration of 6.4 mg/l
[2]. The peak plasma concentration of indinavir in
patients at the recommended dose of 400–800 mg is
already 8–10 mg/l [3]. Within 3 h after a typical
indinavir dosage of 800 mg orally in a patient
averaging 1.5 l urine output daily, the urine concen-
tration already exceeds the limits of solubility at 200–
300 mg/l making crystal formation likely common
[3]. Current recommendations to prevent nephrolithi-
asis include hydration with at least 1.5 l of ﬂuids
daily to increase the clearance of indinavir [2].
In the clinical setting, many factors may increase
the risk of indinavir crystallization in urine with the
most important being volume depletion leading to
higher urine drug concentration. Other cited risk
factors include variations in individual pharmacoki-
netics of indinavir, hepatic insufﬁciency leading to
greater dependence on renal clearance, differences in
plasma protein binding of indinavir, low urinary pH
decreasing indinavir solubility, renal insufﬁciency,
renal tubular cell injury as a predisposition for crystal
adherence and agglomeration, and low lean body
mass [3, 4]. It is important to note that the effect of
Fig. 1 Kidney biopsy showing crystal-induced tubular injury
with rupture
Fig. 2 Electron microscopy showing granulomatous giant cell
reaction with crystals within the lumen
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navir has not been studied well.
In the patient presented, a kidney biopsy demon-
strated crystal-induced tubular injury with rupture
and electron microscopy revealed granulomatous
giant cell reaction with crystals within the lumen.
Even though the patient had discontinued indinavir
for 1.5 years by the time of renal biopsy, the crystals
remained in the renal tubules. One hypothesis of
stone formation long after discontinuation of indina-
vir is that the soft, gelatinous nature of indinavir
crystals allows it to gradually collect and build up
within the renal tubules with time and when a critical
mass of indinavir crystals develops, it precipitates
into an obstructing stone [5].
A second hypothesis for stone formation centers
on low lean body mass that results in a low
distribution volume of indinavir and hence a higher
plasma concentration of indinavir [4]. Since dosing of
indinavir is independent of body mass, plasma
concentrations of indinavir may vary greatly among
patients on the same dose. The higher plasma
concentration leads to a higher urinary concentration
of indinavir that increases the risk of crystal and stone
formation.
The detection of indinavir itself poses another
challenge as no single imaging modality proves
superior in deﬁnitively diagnosing indinavir stones.
One study found that no abdominal imaging study is
diagnostic, intravenous pyelogram detects less than
8% of indinavir stones, renal ultrasounds demon-
strated obstruction in 82% of cases, and CT imaging
revealed obstruction with no stones in over 50% of
the cases [4]. Stones that were visible on CT were
more likely of mixed composition, containing indi-
navir with radioopaque substances such as calcium or
uric acid [4]. Accurate diagnosis is important as
conservative management is often effective, but some
cases may require ureteral stenting to relieve obstruc-
tion [6].
Conclusion
This case is an important illustration of how indinavir-
induced nephrolithiasis can present many years after
the discontinuation of therapy. Nephrolithiasis is an
important differential diagnosis for any patient with a
history of indinavir use presenting with symptoms of
ﬂankpainand/orhematuria.Typicalmeansofimaging
may not be diagnostic and failure to visualize a stone
insufﬁcient to rule out nephrolithiasis. Since urinary
concentrations may vary from patient to patient on
similar dosages of indinavir, future management may
require titrating dosages to yield urinary concentra-
tions below the maximum solubility of indinavir to
minimize risk of nephrolithiasis.
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